Literature DB >> 8176573

High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms.

R A Hrachovy1, J D Frost, D G Glaze.   

Abstract

Fifty patients in whom the diagnosis of infantile spasms had recently been made and who had hypsarrhythmic electroencephalographic findings were randomly assigned to receive either high- or low-dose therapy with corticotropin (adrenocorticotropic hormone; ACTH). Twenty-six patients receiving the high-dose therapy were treated as follows: 150 U/m2 per day for 3 weeks, 80 U/m2 per day for 2 weeks, 80 U/m2 every other day for 3 weeks, and 50 U/m2 per day every other day for 1 week, with the dosage then tapered to zero during a 3-week period. The 24 patients assigned to the low-dose therapy group received 20 to 30 U/day for 2 to 6 weeks; the dosage was then tapered to zero during a 1-week period. Population characteristics (cryptogenic vs symptomatic, treatment lag, and age at start of treatment) of the two groups were similar. Response, defined as cessation of spasms and disappearance of hypsarrhythmia, was determined objectively by serial prolonged video and polygraphic monitoring studies. Of the 26 patients treated with the high-dose therapy, 13 (50%) responded; of the 24 patients treated with the low-dose therapy, 14 (58%) responded (p value not significant). No significant difference in the relapse rate between the two groups was observed. The side effects seen in both treatment groups were similar, except that hypertension occurred more frequently in the high-dose group. These results indicate that there is no major difference in the effectiveness of these two regimens in the treatment of infantile spasms with respect to spasm cessation and improvement in the patients' electroencephalographic findings.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8176573     DOI: 10.1016/s0022-3476(05)81379-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  42 in total

1.  Treatment of infantile spasms: the ideal and the mundane.

Authors:  Tallie Z Baram
Journal:  Epilepsia       Date:  2003-08       Impact factor: 5.864

2.  Infantile spasms and epilepsy currents.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2005 Jul-Aug       Impact factor: 7.500

Review 3.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  West Syndrome: A Review and Guide for Paediatricians.

Authors:  Renato D'Alonzo; Donato Rigante; Elisabetta Mencaroni; Susanna Esposito
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

5.  H.p. Acthar gel and cosyntropin review: clinical and financial implications.

Authors:  Jacob Gettig; Joseph P Cummings; Karl Matuszewski
Journal:  P T       Date:  2009-05

6.  Corticotrophin-ACTH in Comparison to Prednisolone in West Syndrome - A Randomized Study.

Authors:  Vykuntaraju K Gowda; Vindhya Narayanaswamy; Sanjay K Shivappa; Naveen Benakappa; Asha Benakappa
Journal:  Indian J Pediatr       Date:  2018-09-19       Impact factor: 1.967

7.  Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms.

Authors:  Jinghua Yin; Qianjin Lu; Fei Yin; Ying Wang; Fang He; Liwen Wu; Lifen Yang; Xiaolu Deng; Chen Chen; Jing Peng
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

Review 8.  Infantile spasms--evidence based medical management.

Authors:  Jitendra Kumar Sahu
Journal:  Indian J Pediatr       Date:  2014-07-02       Impact factor: 1.967

Review 9.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 10.  Role of brain inflammation in epileptogenesis.

Authors:  Jieun Choi; Sookyong Koh
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.